General Dermatology

Learn more about the in-depth topics covered in the June 2025 print issue of Dermatology Times.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

Dermatology Times is looking back on the top stories in dermatology from the month of June.

At SDPA 2025, a poster evaluating the STRATUM trial showed roflumilast foam 0.3% effectively treats seborrheic dermatitis with minimal pigment changes.

A yearlong study showed dupilumab alone effectively prevented flares in moderate to severe atopic dermatitis, with consistent safety across various dosing schedules.

A poster at SDPA highlights that dermatologists play a vital role in early detection of metastatic breast cancer, with skin changes often serving as the initial clue of internal disease recurrence.

Almirall showcased groundbreaking research on atopic dermatitis, psoriasis, and actinic keratosis at the 2025 ICD.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Dermatology Times is recapping our exclusive expert interviews from the month of June.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Renata Block, DMSc, MMS, PA-C, speaks with Adam Friedman, MD, FAAD, on innovative teledermatology initiatives in Washington, DC, addressing health care disparities and enhancing community access.

Discover Hershel Dobkin's unique blend of humor and dermatology, offering insights that combat clinical burnout and bring joy to medical practice.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Explore the top headlines of the week including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news about the FDA approval of dupilumab for bullous pemphigoid, the upcoming INTEGUMENT-INFANT trial for roflumilast, nail trends that challenge clinical diagnosis, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Dupilumab gains FDA approval as the first targeted therapy for bullous pemphigoid, offering hope for effective treatment and improved patient outcomes.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Upadacitinib’s targeted inhibition of JAK1 offers a novel strategy for managing bullous pemphigoid and, in rare, treatment-resistant cases, may induce sustained remission following immune modulation.

Researchers conducted a systematic review to summarize research that has addressed social media’s impact on skin health promotion activities.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

LGBTQ+-inclusive language in dermatology enhances patient care, addresses health barriers, and improves outcomes for transgender individuals facing acne challenges.

This review of the latest dermatologic studies includes insights into differences in vitamin D levels in rosacea versus healthy individuals, psychosocial determinants and atopic dermatitis outcomes, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.